Cargando…

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still scarce and are important to design vaccination strategies. In this study, 231 healthcare professionals received the two-dose regimen of BNT162b2. Of these, 158 were seronegative and 73 were seropositive at baselin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayart, Jean-Louis, Douxfils, Jonathan, Gillot, Constant, David, Clara, Mullier, François, Elsen, Marc, Eucher, Christine, Van Eeckhoudt, Sandrine, Roy, Tatiana, Gerin, Vincent, Wieers, Grégoire, Laurent, Christine, Closset, Mélanie, Dogné, Jean-Michel, Favresse, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540417/ https://www.ncbi.nlm.nih.gov/pubmed/34696200 http://dx.doi.org/10.3390/vaccines9101092

Ejemplares similares

Antibody titres decline 3-month post-vaccination with BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
por: Favresse, Julien, et al.
Publicado: (2021)

Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
por: Favresse, Julien, et al.
Publicado: (2022)

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
por: Favresse, Julien, et al.
Publicado: (2022)

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
por: Favresse, Julien, et al.
Publicado: (2021)

Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
por: Catry, Emilie, et al.
Publicado: (2022)

Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection
por: Favresse, Julien, et al.
Publicado: (2021)

An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens
por: Gillot, Constant, et al.
Publicado: (2020)

Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals
por: Bayart, Jean-Louis, et al.
Publicado: (2023)

NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments
por: Gillot, Constant, et al.
Publicado: (2021)

Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome
por: Gillot, Constant, et al.
Publicado: (2022)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Gillot, Constant, et al.
Publicado: (2021)

High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies
por: Mairesse, Antoine, et al.
Publicado: (2020)

Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant
por: Bayart, Jean-Louis, et al.
Publicado: (2022)

Post-SARS-CoV-2 vaccination specific antibody decrease — Thresholds for determining seroprevalence and seroneutralization differ
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity
por: Favresse, Julien, et al.
Publicado: (2022)

Reply to Schulte-Pelkum, J. Comment on “Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556”
por: Favresse, Julien, et al.
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
por: Suah, Jing Lian, et al.
Publicado: (2022)

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls
por: Evrard, Jonathan, et al.
Publicado: (2022)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
por: Hatzakis, Angelos, et al.
Publicado: (2022)

Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination
por: Cimas, Francisco J., et al.
Publicado: (2023)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
por: Szekanecz, Zoltán, et al.
Publicado: (2023)

Waning Humoral Response 6 Month after Double Vaccination with the mRNA-BNT162b2 Vaccine in Hemodialysis Patients
por: Balčiuvienė, Vilma, et al.
Publicado: (2023)

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis
por: Haguet, Hélène, et al.
Publicado: (2020)

Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels
por: Douxfils, Jonathan, et al.
Publicado: (2021)

BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
por: Rudan, Igor, et al.
Publicado: (2022)

Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2022)

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
por: Douxfils, Jonathan, et al.
Publicado: (2014)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
por: Berar-Yanay, Noa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dn5o3nbkuuvqf1aj4pqpgvgavr